Option Care nabs exclusive distribution contract for Vyjuvek
By HME News Staff
Updated 9:33 AM CDT, Wed May 24, 2023
%20(1).jpg)
BANNOCKBURN, Ill. – Option Care Health has been selected by Krystal Biotech as part of a limited distribution specialty pharmacy network for Vyjuvek, which was recently approved by the U.S. Food & Drug Administration for the treatment of patients with dystrophic epidermolysis bullosa (DEB). Through its national footprint of more than 95 specialty pharmacies, Option Care will serve as the only specialty pharmacy provider for mixing and delivering prepared Vyjuvek gel administration syringes to professional health care and home settings. “We are honored to work with Krystal Biotech in providing access to this novel treatment, which is expected to help children and adults suffering from a rare disease,” said John Rademacher, president and CEO of Option Care. “The ability to administer this non-invasive treatment in the comfort of one’s home will help ensure that this medicine gets to those who need it the most.” Option Care will collaborate with Amedisys on this effort, with Amedisys nurses delivering and administering the drug to patients. Amedisys is a leading health care at home company that has a strong presence in hospital-at-home, home health, hospice, palliative, and high-acuity care services. Option Care announced in early May that it entered into a merger agreement with Amedisys.
Comments